About Us
Anaconda Pharma is a privately held biopharmaceutical company incorporated in November 2003 and originally operating from lab space within the BioTop incubator at the Pasteur Institute campus in Paris. Anaconda Pharma is now located at the BioPark in Paris, France.
Anaconda Pharma has developed a unique and proprietary platform for the discovery of small molecules that disrupt protein:protein interactions. These represent a major new class of pharmaceutical targets which have been unexploited due to the difficulty of recognizing drug'able hot-spots on the surface of interacting proteins. Anaconda Pharma’s unique technology platform includes:
-
proprietary high definition crystallographic 3-D information on targets,
-
proprietary cellular and in vitro screening assays, and
-
patented lead molecules & series amenable to optimisation.
Anaconda Pharma is initially targeting condyloma, an HPV related-indication which represents the major HPV economic opportunity in industrialized countries. The Company is currently focused on establishing clinical proof of principle for its technology platform in this indication, but also intends to exercise its capacity to target other HPV indications, including:
-
dermal warts,
-
recurrent respiratory papillomatosis, and
-
anogenital dysplasia.
Printable Page
 |
< HOME PAGE | © 2006 Anaconda Pharma |  |